Clinical trial registry record

Bevacizumab and Temsirolimus in Treating Patients With Recurrent or Persistent Endometrial Cancer

A registered PHASE2 study indexed because it matched monitored longevity research terms. Registry status: Completed. Registration does not establish safety or effectiveness.

Registry ID
NCT00723255
Last registry update
July 23, 2019
Status
Completed
Phase
PHASE2
Sponsor
National Cancer Institute (NCI)
Enrollment
53
Countries
United States
Match confidence
80%
Source feed
ClinicalTrials.gov
Automated source synopsis

A registered PHASE2 study indexed because it matched monitored longevity research terms. Registry status: Completed. Registration does not establish safety or effectiveness.

Registration and recruitment status do not establish safety, efficacy, or regulatory approval.

Why this record matched · 80% confidence

Published automatically with 80% topic confidence after controlled-term evaluation.

  • Rapamycin · 80%Legacy trial evaluated automatically against controlled title, summary, and longevity-context rules.

Source quality 100% · freshness 50%. These are automated routing signals, not medical or evidence-strength ratings.